skip navigation

Skip Nav

HIV/AIDS Clinical Trials

Clinical Trial Search Results

309 studies were found about ( Truvada OR emtricitabine AND tenofovir disoproxil fumarate )

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV; HIV Infections

NCT ID: NCT01106586

Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01475838

Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01495702

FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women

Condition: HIV Infections

NCT ID: NCT00625404

Effects of Contingency Management for Methamphetamine Abstinence on Post-Exposure Prophylaxis for HIV in Men Who Have Sex With Men (MSM)

Condition: Amphetamine-Related Disorders; HIV; HIV Infections

NCT ID: NCT00856323

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

Condition: Acute HIV Infection; HIV Infections

NCT ID: NCT00924898

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women (WAVES)

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01705574

ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

Condition: Human Immunodeficiency Virus (HIV)

NCT ID: NCT00335322

Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients

Condition: Hepatitis B; HIV Infections

NCT ID: NCT00391638

Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00762892

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

Condition: HIV Infections

NCT ID: NCT00959894

Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

Condition: HIV Infections

NCT ID: NCT00544128

Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)

Condition: HIV Infections

NCT ID: NCT00573001

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

Condition: HIV Infection

NCT ID: NCT00244712

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

Condition: HIV Infections

NCT ID: NCT00323544

On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men

Condition: HIV Infection

NCT ID: NCT01473472

Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01565850

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

Condition: HIV Infections

NCT ID: NCT01040091

Safety and Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disoproxil Fumarate Tablets in Preventing HIV in Women

Condition: HIV Infections

NCT ID: NCT00705679

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples

Condition: HIV-1 Infections; HIV Infections

NCT ID: NCT00557245

Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).

Condition: HIV Infection

NCT ID: NCT01769469

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Condition: HIV-2 Infection

NCT ID: NCT01605890

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Condition: HIV

NCT ID: NCT01214759

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Condition: HIV Infections

NCT ID: NCT00112047

A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

Condition: HIV Infections

NCT ID: NCT00369941

KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects

Condition: Infection, Human Immunodeficiency Virus I; HIV Infection

NCT ID: NCT00549198

Safety and Efficacy of GS-9350-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV-1 Infection

NCT ID: NCT00892437

Pre-exposure Option for Reducing HIV in the UK.(PROUD)

Condition: HIV

NCT ID: NCT02065986

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Condition: HIV Infections

NCT ID: NCT00528060

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

Condition: HIV Infections

NCT ID: NCT01632345

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

Condition: HIV Infections

NCT ID: NCT00106379

Raltegravir Activity In Lymphoid Tissues

Condition: HIV Infection; HIV Infections

NCT ID: NCT00863668

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Condition: HIV Infections

NCT ID: NCT00525733

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

Condition: HIV Infection; Osteopenia

NCT ID: NCT01902186

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

Condition: HIV Infections

NCT ID: NCT00551018

Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

Condition: HIV; HIV Infections

NCT ID: NCT01108510

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

Condition: HIV Infections; Hepatitis B

NCT ID: NCT00662545

GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

Condition: HIV Infections

NCT ID: NCT00105079

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men

Condition: HIV Prevention; HIV Infections

NCT ID: NCT01087840

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

Condition: HIV-1 Infections

NCT ID: NCT01033760

GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance

Condition: HIV Infections

NCT ID: NCT00362687

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Condition: HIV-1 Infection

NCT ID: NCT01338883

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

Condition: HIV Infections; Acquired Immune Deficiency Syndrome

NCT ID: NCT01173510

Safety and Efficacy Study of Switching From Epzicom to Truvada

Condition: HIV Infection

NCT ID: NCT00724711

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)

Condition: HIV Infection

NCT ID: NCT01576731

A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

Condition: HIV-1

NCT ID: NCT00824421

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Condition: HIV; HIV Infections

NCT ID: NCT01797445

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

Condition: HIV Infections

NCT ID: NCT00552240

Botswana TDF/FTC Oral HIV Prophylaxis Trial

Condition: HIV Infections

NCT ID: NCT00448669

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Condition: HIV; HIV Infections

NCT ID: NCT01780506

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

Condition: HIV Infections

NCT ID: NCT00654147

TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada

Condition: HIV Infections

NCT ID: NCT00323492

PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers

Condition: HIV Infection; HIV Infections

NCT ID: NCT01108926

A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection

Condition: Infection; HIV

NCT ID: NCT01697046

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

Condition: HIV; HIV Infections

NCT ID: NCT00928187

Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01497899

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Condition: Human Immunodeficiency Virus-1

NCT ID: NCT00827112

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1

NCT ID: NCT01345630

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Condition: HIV Infections

NCT ID: NCT00224445

Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

Condition: HIV Infections

NCT ID: NCT00389207

Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)

Condition: HIV Infections; AIDS

NCT ID: NCT00302822

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

Condition: HIV Infection; Hepatitis C

NCT ID: NCT00121017

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

Condition: HIV Infections

NCT ID: NCT00729573

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

Condition: HIV

NCT ID: NCT00931801

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

Condition: HIV

NCT ID: NCT00960622

Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection

Condition: Acute HIV Infection

NCT ID: NCT00734344

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

Condition: HIV Infections

NCT ID: NCT00076791

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01533259

Combination of Efavirenz and Truvada - COMET Study

Condition: HIV Infections

NCT ID: NCT00224458

Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine

Condition: HIV+

NCT ID: NCT01813292

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

Condition: HIV Infection

NCT ID: NCT01505114

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)

Condition: HIV Infection

NCT ID: NCT01533272

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Condition: Human Immunodeficiency Virus

NCT ID: NCT01180075

A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services

Condition: HIV Prevention

NCT ID: NCT01781806

Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

Condition: HIV Infections

NCT ID: NCT01114425

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV-1 Infection

NCT ID: NCT01309243

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Condition: Hepatitis C; HIV

NCT ID: NCT01565889

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

Condition: HIV Infections

NCT ID: NCT00808002

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

Condition: Human Immunodeficiency Virus-type 1 Infection

NCT ID: NCT01709084

Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis

Condition: Tuberculosis; HIV Infections

NCT ID: NCT00474435

Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

Condition: HIV-1 Infection

NCT ID: NCT01772940

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men

Condition: HIV Infections

NCT ID: NCT00458393

Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults

Condition: HIV Infections

NCT ID: NCT00608569

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

Condition: HIV Transmission; HIV Infections

NCT ID: NCT00949234

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

Condition: HIV Infection

NCT ID: NCT01772823

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

Condition: HIV Infection

NCT ID: NCT01769456

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Condition: HIV; HIV Infections; Acquired Immunodeficiency Syndrome

NCT ID: NCT01967940

Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01721109

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Condition: HIV Infections

NCT ID: NCT01066962

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Condition: HIV Infections

NCT ID: NCT00272779

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Condition: Human Immunodeficiency Virus Type 1

NCT ID: NCT00110305

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Condition: HIV Infections

NCT ID: NCT00074581

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

Condition: HIV Infection; Hepatitis C

NCT ID: NCT01285050

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Condition: HIV Infections; Hepatitis B

NCT ID: NCT00127959

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Condition: HIV Infections

NCT ID: NCT00660972

Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients

Condition: HIV Infections

NCT ID: NCT00543803

Raltegravir as Early Therapy in African-Americans Living With HIV Study

Condition: HIV Infections

NCT ID: NCT00667433

SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada

Condition: HIV-1 Infection

NCT ID: NCT00323687

Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)

Condition: HIV Infections

NCT ID: NCT00346567

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

Condition: HIV

NCT ID: NCT01602822

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

Condition: HIV Infections

NCT ID: NCT00442962

Clinical Trial of CNS-targeted HAART (CIT2)

Condition: HIV Infections

NCT ID: NCT00624195

ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial

Condition: HIV-1

NCT ID: NCT00772902

Raltegravir Switch for Toxicity or Adverse Events

Condition: HIV/AIDS; Antiretroviral Therapy; HIV Infections

NCT ID: NCT00958100

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

Condition: HIV-1 Infection

NCT ID: NCT01286740

Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

Condition: HIV; Dyslipidemia

NCT ID: NCT01458977

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01102972

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Condition: Human Immunodeficiency Virus Infection

NCT ID: NCT00711009

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

Condition: HIV Infections

NCT ID: NCT00632970

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

Condition: HIV Infections

NCT ID: NCT00885664

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

Condition: HIV-1

NCT ID: NCT00324649

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

Condition: HIV

NCT ID: NCT00757783

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Condition: HIV-1 Infection

NCT ID: NCT01252940

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Condition: HIV Infections

NCT ID: NCT02116660

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Condition: HIV Infections; Tuberculosis

NCT ID: NCT00115609

Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl

Condition: HIV Infections

NCT ID: NCT00532168

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

Condition: HIV Infections

NCT ID: NCT00192634

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

Condition: HIV-1 Infection

NCT ID: NCT00534352

Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.

Condition: HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men

NCT ID: NCT01715636

Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP

Condition: HIV; Pregnancy

NCT ID: NCT00204308

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

Condition: HIV Infections

NCT ID: NCT01327651

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Condition: HIV Infections

NCT ID: NCT00118898

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01910402

Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir

Condition: HIV Infections

NCT ID: NCT01294761

Atripla to Raltegravir Switch Study

Condition: HIV Infection

NCT ID: NCT01195467

Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey

Condition: HIV Infection

NCT ID: NCT01322932

Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism

Condition: HIV Infections

NCT ID: NCT00759070

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

Condition: HIV; Impaired Cognition

NCT ID: NCT01367236

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

Condition: HIV

NCT ID: NCT01270802

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

Condition: HIV Infections

NCT ID: NCT00414635

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

Condition: HIV

NCT ID: NCT00745823

Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

Condition: Chronic Hepatitis B; HIV Infections

NCT ID: NCT00221286

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Condition: HIV Infections

NCT ID: NCT00594646

Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Condition: Acquired Immune Deficiency Syndrome (AIDS); HIV Infections

NCT ID: NCT01854775

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

Condition: HIV Infections

NCT ID: NCT00043966

Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.

Condition: Prevention and Control; Preventive Measures; Preventive Therapy; Prophylaxis; HIV Not Infected Subjects

NCT ID: NCT01989611

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Condition: HIV

NCT ID: NCT01003990

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Condition: HIV Infections; HIV-1; Human Immunodeficiency Virus Type 1

NCT ID: NCT00540449

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Condition: HIV; HIV Infections

NCT ID: NCT01818596

Artery Elasticity After Switch From Epzicom to Truvada

Condition: HIV Infections

NCT ID: NCT00998582

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

Condition: HIV Disease

NCT ID: NCT01929759

The First Failure Study

Condition: HIV; HIV Infections

NCT ID: NCT01118871

Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

Condition: HIV

NCT ID: NCT02104700

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

Condition: Immune Reconstitution Inflammatory Syndrome; HIV; HIV Infections

NCT ID: NCT00988780

A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication

Condition: HIV Infection

NCT ID: NCT01865786

Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects

Condition: HIV; HIV Infections

NCT ID: NCT01815736

HIV Non-Occupational Post-Exposure Prophylaxis

Condition: Human Immunodeficiency Virus

NCT ID: NCT01855867

Intense Acute Infection Study

Condition: Acute HIV Infection

NCT ID: NCT01154673

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.

Condition: HIV; Cardiovascular Disease

NCT ID: NCT01258439

Anti-Retrovirals for Kaposi's Sarcoma

Condition: Kaposi's Sarcoma; HIV Infections

NCT ID: NCT00444379

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Condition: HIV-1; HIV Infections; Acquired Immunodeficiency Syndrome

NCT ID: NCT01968551

A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine

Condition: HIV Infection

NCT ID: NCT01159743

Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV; HIV Infections

NCT ID: NCT01095796

A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA

Condition: Pre-exposure Prophylaxis for Prevention of HIV Infection

NCT ID: NCT01865799

Phase IIB Pilot of Atazanavir + Raltegravir

Condition: HIV

NCT ID: NCT00768989

VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients

Condition: HIV Infections

NCT ID: NCT00561925

SCOPE: Strategies to Combine PrEP With Prevention Efforts

Condition: HIV

NCT ID: NCT01832571

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Condition: HIV; HIV Infections

NCT ID: NCT00869557

Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)

Condition: HIV Infection

NCT ID: NCT00158457

A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP

Condition: HIV Infections

NCT ID: NCT00669487

Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

Condition: HIV Infections

NCT ID: NCT01061151

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Condition: HIV-1 Infection

NCT ID: NCT01400412

Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)

Condition: HIV Infection; Pregnancy

NCT ID: NCT00334256

Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy

Condition: HIV Infection

NCT ID: NCT02097381

Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

Condition: Stimulant-Related Disorders; HIV; HIV Infections

NCT ID: NCT01140880

Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)

Condition: HIV Infections

NCT ID: NCT00705419

Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy

Condition: HIV Infections

NCT ID: NCT00357552

Seroconversions, Resistance, Adverse Events and Drug Adherence Among Subjects Taking Truvada® for PrEP: A Case Control Study

Condition: HIV

NCT ID: NCT01906255

A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)

Condition: HIV

NCT ID: NCT01902472

HIV Persistence and Viral Reservoirs

Condition: HIV; HIV Infections

NCT ID: NCT01025427

Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE)

Condition: HIV

NCT ID: NCT01253538

Post-Exposure Prophylaxis in Health Care Workers

Condition: Human Immunodeficiency Virus

NCT ID: NCT01234116

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults

Condition: HIV; HBV

NCT ID: NCT02071082

Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients

Condition: HIV

NCT ID: NCT01291459

Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients

Condition: HIV Infections

NCT ID: NCT00365612

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

Condition: HIV Infections

NCT ID: NCT00051831

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

Condition: Hepatitis C; HIV Infections

NCT ID: NCT00545558

BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes

Condition: HIV Infections

NCT ID: NCT00389402

FTC/RPV/TDF on T-Cell Activation, CD4 Cell Count, Inflammatory Biomarkers and Viral Reservoir

Condition: HIV-1 Infection

NCT ID: NCT01777997

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01641809

ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla

Condition: HIV Infections

NCT ID: NCT00615745

PREventing Progression of Adipose Tissue Redistribution

Condition: HIV Infections

NCT ID: NCT00389194

Atazanavir/Ritonavir (ATV/RTV) Once a Day (QD) + Raltegravir (RAL) Twice a Day (BID) Stable Switch Study

Condition: HIV, Combination Therapy

NCT ID: NCT01332227

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected

Condition: HIV-1 Infection; Pf Subclinical Parasitemia

NCT ID: NCT01632891

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01231555

Pre-Exposure Prophylaxis in YMSM

Condition: HIV

NCT ID: NCT01033942

Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infection

NCT ID: NCT00811954

Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet

Condition: HIV

NCT ID: NCT01694420

Three Month Course of Anti-HIV Medications for People Recently Infected With HIV

Condition: HIV Infections

NCT ID: NCT00087464

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

Condition: HIV Infections

NCT ID: NCT00677300

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

Condition: HIV Infections

NCT ID: NCT00414518

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

Condition: HIV

NCT ID: NCT01687218

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Condition: HIV Infections

NCT ID: NCT00752856

Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection

Condition: Hepatitis B Virus; HIV Infections

NCT ID: NCT00476463

Single Dose Truvada in HIV-negative Men and Women

Condition: Pharmacokinetic Study in Healthy Volunteers

NCT ID: NCT01326221

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

Condition: HIV-1

NCT ID: NCT01274780

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Condition: Acquired Immune Deficiency Syndrome

NCT ID: NCT00775606

Study of Options for Second-Line Effective Combination Therapy (SELECT)

Condition: HIV-1 Infection

NCT ID: NCT01352715

Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics

Condition: HIV Infections

NCT ID: NCT01632995

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Condition: HIV Infection

NCT ID: NCT01380080

A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

Condition: HIV

NCT ID: NCT01701882

Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults

Condition: HIV Infections

NCT ID: NCT00820118

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

Condition: Human Immunodeficiency Virus Infection

NCT ID: NCT01869634

The Mochudi Prevention Project ART Protocol

Condition: HIV Infections

NCT ID: NCT01583439

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Condition: HIV Infections

NCT ID: NCT00084136

Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers

Condition: HIV

NCT ID: NCT01276600

Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers

Condition: HIV

NCT ID: NCT01796431

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Condition: HIV-1 Infection

NCT ID: NCT01641367

Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy

Condition: HIV Infections

NCT ID: NCT00099632

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation

Condition: HIV Infections

NCT ID: NCT00036452

RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients

Condition: Chronic Infection With HIV

NCT ID: NCT01829802

Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine

Condition: HIV

NCT ID: NCT01694407

NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission

Condition: HIV Infections

NCT ID: NCT00089505

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Condition: HIV-1 Infection

NCT ID: NCT01803074

A Key Link for Transmission Prevention

Condition: HIV

NCT ID: NCT01450189

Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00876733

Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma

Condition: HIV-1 Infection; Kaposi's Sarcoma

NCT ID: NCT01352117

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Condition: HIV

NCT ID: NCT01778413

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

Condition: HIV

NCT ID: NCT01348763

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

Condition: HIV Infected

NCT ID: NCT01394133

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Condition: Human Immuno Deficiency (HIV) Infections

NCT ID: NCT00799864

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

Condition: HIV Infections

NCT ID: NCT00090779

Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study

Condition: HIV Infections

NCT ID: NCT00537966

"The Once A Day Protease Inhibitor Regimens"

Condition: HIV Infections

NCT ID: NCT00242216

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

Condition: Tuberculosis

NCT ID: NCT01690403

Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment

Condition: HIV; AIDS; Tuberculosis

NCT ID: NCT00737724

Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera

Condition: HIV-1 Infection

NCT ID: NCT01701895

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

Condition: HIV-1 Infection

NCT ID: NCT01403051

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Condition: HIV-1 Infection

NCT ID: NCT01515813

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

Condition: Hepatitis C, Chronic; HIV Infection

NCT ID: NCT01147107

A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine

Condition: HIV

NCT ID: NCT00344461

The Raltegravir 60+ Study

Condition: HIV

NCT ID: NCT01335620

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

Condition: HIV

NCT ID: NCT01293123

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Condition: HIV; Hepatitis C

NCT ID: NCT01225705

Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3

Condition: HIV-1 Infection

NCT ID: NCT02057796

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

Condition: HIV-1 Infections

NCT ID: NCT00984152

Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial

Condition: HIV Infection; Pregnancy; Breastfeeding; HIV Infections

NCT ID: NCT00936195

Sex, Aging and Antiretroviral Pharmacokinetics

Condition: HIV Infections

NCT ID: NCT00666055

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Condition: HIV

NCT ID: NCT01620944

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women

Condition: HIV

NCT ID: NCT01815580

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Condition: HIV Infections; Treatment Naive

NCT ID: NCT00851799

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

Condition: HIV; HIV-associated Neurocognitive Disorder; Neurotoxicity

NCT ID: NCT01978743

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection

Condition: HIV Infection

NCT ID: NCT00641641

Sustainable Healthcenter Implementation PrEP Pilot Study

Condition: HIV Chemoprophylaxis; HIV Preexposure Prophylaxis

NCT ID: NCT02074891

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT00951015

A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL

Condition: Lymphoma, AIDS Related; HIV Infections

NCT ID: NCT00799136

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial

Condition: HIV Infections

NCT ID: NCT00615810

The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)

Condition: HIV Infection

NCT ID: NCT01271894

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

Condition: HIV Infections; AIDS-Related Opportunistic Infections

NCT ID: NCT00055120

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

Condition: HIV-1 Infection; Immunosuppression-related Infectious Disease

NCT ID: NCT01928407

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

Condition: HIV Infections

NCT ID: NCT00102206

MARCH Central Nervous System Substudy

Condition: HIV-1 Infection

NCT ID: NCT01637233

Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+

Condition: HIV Seropositivity

NCT ID: NCT01174914

A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir

Condition: HIV

NCT ID: NCT01255371

QoL and Adherence to One-pill Once-a-day HAART

Condition: HIV Infection; HIV Infections

NCT ID: NCT00990600

The Rilpivirine Cerebrospinal-fluid (CSF) Study

Condition: HIV

NCT ID: NCT01562886

Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria

Condition: HIV Infections; Proteinuria

NCT ID: NCT01044771

Sustainable East Africa Research in Community Health

Condition: HIV; Tuberculosis; Hypertension; Diabetes; Maternal Child Health; Cost Effectiveness

NCT ID: NCT01864603

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01363011

MARCH Renal Substudy

Condition: Proteinuria; HIV

NCT ID: NCT01637259

Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

Condition: HIV

NCT ID: NCT01694017

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

Condition: Leukoencephalopathy, Progressive Multifocal; HIV Infections

NCT ID: NCT00120367

A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients

Condition: HIV

NCT ID: NCT00199121

Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

Condition: HIV

NCT ID: NCT01712425

Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients

Condition: Cardiovascular Disease; HIV Infections

NCT ID: NCT01066065

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects

Condition: Impaired Cognition; Depression/Anxiety; Poor Quality Sleep; Quality of Life; HIV-1 Infection

NCT ID: NCT02042001

Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg

Condition: Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID

NCT ID: NCT00476983

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

Condition: HIV

NCT ID: NCT01343225

CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM

Condition: Patient Adherence; HIV Seronegativity

NCT ID: NCT01761643

Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir

Condition: HIV Infections

NCT ID: NCT00214890

Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS

Condition: HIV-1 Infection

NCT ID: NCT01435018

Intensive Viral Dynamics Substudy of A5248

Condition: HIV Infections; Treatment Naive

NCT ID: NCT00852618

Immune Responses in Patients Treated With Raltegravir

Condition: HIV Infections

NCT ID: NCT00785967

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

Condition: HIV Infection

NCT ID: NCT00931346

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

Condition: HIV Infections

NCT ID: NCT00971230

Early HIV Therapy in Patients With High CD4 Cell Counts

Condition: HIV

NCT ID: NCT01479634

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Condition: Infection, Human Immunodeficiency Virus I

NCT ID: NCT01263015

Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract

Condition: Women's Health; HIV Infection; Genital Diseases, Female

NCT ID: NCT01456962

Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients

Condition: HIV Infections; Lipoatrophy

NCT ID: NCT00978237

HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

Condition: HIV

NCT ID: NCT01808352

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

Condition: HIV Infections

NCT ID: NCT00627055

Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)

Condition: HIV Infections

NCT ID: NCT00312169

Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

Condition: HIV Infection

NCT ID: NCT01474954

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01449929

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

Condition: HIV Infections

NCT ID: NCT00039741

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Condition: HIV-1

NCT ID: NCT01254656

Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events

Condition: HIV-Infection

NCT ID: NCT01417949

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

Condition: HIV Infections; Hepatitis C

NCT ID: NCT01105611

Antiretroviral Therapy for Acute HIV Infection

Condition: Acute HIV Infection

NCT ID: NCT00796263

Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence

Condition: HIV Infection

NCT ID: NCT01509508

Preliminary Study of Zidovudine Addition for HIV-associated Neurocognitive Disorder

Condition: HIV Associated Neurocognitive Disorder

NCT ID: NCT01966094

Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

Condition: HIV Infections

NCT ID: NCT01159223

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01458132

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).

Condition: HIV; Depression

NCT ID: NCT01978782

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Condition: Healthy Subjects; Infection, Human Immunodeficiency Virus

NCT ID: NCT01366547

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01622790

Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women

Condition: Vertical Disease Transmission; HBV

NCT ID: NCT02044068

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Condition: Human Immunodeficiency Virus Infections

NCT ID: NCT00262522

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

Condition: Human Immunodeficiency Virus (HIV) Infections; Acquired Immunodeficiency Syndrome (AIDS) Virus

NCT ID: NCT01448707

Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)

Condition: HIV Infection

NCT ID: NCT00707733

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

Condition: HIV Infection; Tuberculosis

NCT ID: NCT00108862

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Condition: HIV

NCT ID: NCT01605084

Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)

Condition: HIV

NCT ID: NCT02043015

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Condition: Infection, Human Immunodeficiency Virus I

NCT ID: NCT01227824

Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals.

Condition: HIV Infections

NCT ID: NCT01011413

Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions

Condition: Human Immunodeficiency Virus; Hepatitis B, Chronic; Hepatitis C, Chronic

NCT ID: NCT01908660

The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1

Condition: HIV Infection

NCT ID: NCT01451333

Situkulwane Lesiphephile-Safe Generations

Condition: HIV/AIDS

NCT ID: NCT01891799

The Neurocognitive Sub-study of Encore1

Condition: HIV

NCT ID: NCT01516060